Compare CUE & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CUE | COHN |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 40.3M |
| IPO Year | 2018 | N/A |
| Metric | CUE | COHN |
|---|---|---|
| Price | $0.30 | $22.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 80.0K |
| Earning Date | 11-12-2025 | 03-09-2026 |
| Dividend Yield | N/A | ★ 4.42% |
| EPS Growth | N/A | ★ 6.29 |
| EPS | N/A | ★ 2.50 |
| Revenue | $7,100,000.00 | ★ $185,475,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | ★ N/A | $9.06 |
| Revenue Growth | N/A | ★ 107.11 |
| 52 Week Low | $0.23 | $6.10 |
| 52 Week High | $1.54 | $32.60 |
| Indicator | CUE | COHN |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 55.71 |
| Support Level | $0.27 | $17.37 |
| Resistance Level | $0.37 | $32.60 |
| Average True Range (ATR) | 0.05 | 2.89 |
| MACD | 0.01 | -0.45 |
| Stochastic Oscillator | 23.35 | 32.67 |
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.